ClinicalTrials.gg
Sign In
Drug

Bulevirtide clinical trials

studies test it
5
open now
1
in phase 3
2
first study started
2019

How each study uses bulevirtide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the bulevirtide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 May 2026 · HEPCLUDEX · BLA 761468 (FDA, Drugs@FDA)
European Union
31 Jul 2020 · Hepcludex · EMEA/H/C/004854 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Hepcludex®
5
Bulevirtide
4
Myrcludex B
4

Studies by the year they started

5 studies that test it; most in 2019 (2)

Studies that test bulevirtide, by start year
YearStudies
20192
20232
20261

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
2
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Hepatitis D, Chronic
1

Who runs them

Industry 5 · Other 0

Gilead Sciences (4) · Mirum Pharmaceuticals, Inc. (1)

Often tested with

Tested in the same studies.

Peginterferon alfa-2a (1) · Brelovitug (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Bulevirtide is the comparator. A study of two new drugs counts under both.

  • 1Brelovitug · Mirum Pharmaceuticals, Inc. · next primary completion Jun 2027
Reaching primary completion within a year · 1, 1 in phase 3

Studies that test bulevirtide, phase 3 first.

Studies

Open first, then newest update. How each study uses bulevirtide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Given beside what is tested · 2 — bulevirtide is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with bulevirtide

Codes

What other systems call bulevirtide · ClinicalTrials.gg INT001669

  • MeSH (NLM) C000718249bulevirtideOne source ClinicalTrials.gov
  • UNII (FDA) WKM56H3TLBBULEVIRTIDEConfirmed FDA, Wikidata
  • Wikidata Q98139660bulevirtideConfirmed FDA, Wikidata
  • NCI Thesaurus C169819BulevirtideOne source FDA
  • DrugBank DB15248One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.